Research - With biotech where it is, we're suggesting taking profits on a number of our big winners in the past 6 months. Here are the details on CEMP, BLUE, TRIL, SAGE, MRNS, SGYP, GBIM, QURE, and TKMR.
Read nowRecap - Investors descend en masse on San Francisco next week for the annual JP Morgan healthcare conference, a major event for the sector that historically generates … Continue Reading
Read nowResearch - Merck is buying Cubist for $102/share, valuing the antibiotics company at $9.5B including its cash. After the close on Monday, the U.S. District Court in Delaware … Continue Reading
PremiumzFree - 2014 has already been a year of M&A records in the biopharmaceutical industry, and on Monday December 8 yet another major transaction occurred, this time … Continue Reading
Read nowRecap - The American Society of Hematology’s annual meeting begins this weekend in San Francisco. It’s a big event for the oncology research community, particularly those studying blood cancers, … Continue Reading
Read nowInsights - Actavis (ACT) continued its acquisition spree on Mondau morning with the purchase of Durata Therapeutics (DRTX) in a deal valued at $675 million. The Dublin based … Continue Reading
Read nowRecap - November is approaching, and the AASLD’s Liver Meeting conference the second week of the month, attracting a bevy of investors this year. The liver has become … Continue Reading
Read now
